Small pri­vate biotechs raise mon­ey in most­ly ear­ly-stage fi­nanc­ing

A trio of biotechs is look­ing to raise funds, to ei­ther kick op­er­a­tions off or to build up re­sources.

Moat Biotech­nol­o­gy, a biotech out of Ok­la­homa City fo­cus­ing on in­tranasal or in­haled ade­n­ovirus vac­cines, an­nounced Tues­day that it raised $6.5 mil­lion in its first close — af­ter launch­ing the com­pa­ny and kick­ing off an ini­tial fund­ing round back in Sep­tem­ber.

Its co-founders — Scott Rollins and Rus­sell Rother — are for­mer Alex­ion ex­ec­u­tives, ac­cord­ing to their LinkedIn pro­files. Rollins, list­ed as one of Alex­ion’s co-founders and for­mer head of drug de­vel­op­ment, left the com­pa­ny in 2008. Rother, Alex­ion’s for­mer sci­ence chief, left in 2010.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.